In this randomized, double-blind, parallel clinical trial involving 108 patients with solid tumours (lung, colorectal, breast) receiving chemo/targeted/immunotherapy, researchers tested a novel nutraceutical formulation (Lipchronic®) comprised of a supercritical rosemary extract high in phenolic diterpenes (carnosic acid/carnosol) combined with alkylglycerols to enhance bioavailability. The formulation was well tolerated, with no major adverse safety signals, and produced significant immune-metabolic modulation: in the lung cancer subgroup it reduced key inflammation biomarkers such as the neutrophil-to-lymphocyte ratio (NLR), increased lymphocyte percentages, decreased neutrophils, and shifted T-cell subpopulations toward effector/memory phenotypes.
Source : https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1519978
